Voluntis and WellDoc Announce innovative Partnership

MHW learned this week that Voluntis and WellDoc — two of the industry’s leading digital therapeutics companies — have inked a commercial agreement aimed at combining Voluntis’ insulin titration technology with WellDoc’s extensive digital coaching platform to create a holistic digital diabetes management solution for patients, providers, health systems and health plans.

From the official word emailed to MHW:

Voluntis developed Insulia, an FDA-cleared, prescription-only digital companion for people and their care teams using basal insulin to treat type 2 diabetes. It provides automated basal insulin dose recommendations for people with type 2 diabetes while enabling the health care team to remotely monitor progress.

The developer of BlueStar® – an FDA-cleared, digital therapeutic for individuals with type 2 diabetes – WellDoc is the first digital health company in the US to conduct randomized clinical trials that demonstrate significant clinical outcomes, as published in multiple peer-reviewed journals and presented at leading industry conferences. The clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for individuals living with type 2 diabetes who used BlueStar.

BlueStar provides real-time and timely individualized coaching and support, as well as educational tools that are actionable and personal for individuals living with type 2 diabetes.

“We are excited to be working with WellDoc so that we can bring together extensive coaching and actionable insulin titration recommendations,” said Voluntis Chief Executive Officer Pierre Leurent. “By bringing both products and these capabilities under the same umbrella, we hope to further simplify treatment for people living with type 2 diabetes.”

This post was written by:

- who has written 2292 posts on mHealthWatch.

Contact the author